1 µg TDENV-PIV with Alum adjuvant

BIOLOGICAL2 trials

Sponsors

U.S. Army Medical Research and Development Command

Conditions

Dengue Fever

Phase 1

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults

CompletedNCT01666652

U.S. Army Medical Research and Development CommandDengue Fever

Start: 2012-09-30End: 2017-11-30Updated: 2019-01-25

A Two-dose Primary Vaccination Study of a Tetravalent Dengue Virus Purified Inactivated Vaccine vs. Placebo in Healthy Adults (in Puerto Rico)

CompletedNCT01702857

U.S. Army Medical Research and Development CommandDengue Fever

Start: 2012-11-30End: 2017-03-23Updated: 2017-05-23

Related Papers

Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.

2022-10-317 citations

Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I Study

American Journal of Tropical Medicine and Hygiene2020-03-0314 citations

Cell-mediated immune responses to different formulations of a live-attenuated tetravalent dengue vaccine candidate in subjects living in dengue endemic and non-endemic regions

Human Vaccines & Immunotherapeutics2019-03-046 citations

Phase I Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico

American Journal of Tropical Medicine and Hygiene2018-03-0643 citations

Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States

American Journal of Tropical Medicine and Hygiene2017-03-1464 citations